Clinical trials: Constipation
Constipation - Functional
Lubiprostone in Children With Functional Constipation
Study to determine if children (6-17 years old) with functional constipation will respond to being treated with lubiprostone for 12 weeks.
- Trial name
- NCT02042183
- Testing
- Lubiprostone
- Where
- 117 sites in United States, Belgium and 5 more
- Volunteers
- 606 people
- Sponsor
- Sucampo Pharma Americas, LLC
Chronic Idiopathic Constipation
Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo
The purpose of this study is to evaluate the bioequivalence of sprinkle and capsule formulations of lubiprostone, as compared to placebo, when administered orally in participants with Chronic Idiopathic Constipation (CIC).
- Trial name
- NCT03097861
- Testing
- Lubiprostone
- Where
- 67 sites in United States
- Volunteers
- 552 people
- Sponsor
- Sucampo Pharma Americas, LLC
Opioid-Induced Constipation
Safety of Subcutaneous Methylnaltrexone for Opioid-Induced Constipation in Patients With Advanced Illness
This is an open-label, multicenter extension of study 3200K1-4000-WW that will evaluate the safety of methylnaltrexone. This drug will be administered by subcutaneous injection and will be tested in late stage, advanced illness…
- Trial name
- NCT00672139
- Testing
- Methylnaltrexone bromide
- Where
- 46 sites in United States, Australia and 8 more
- Volunteers
- 156 people
- Sponsor
- Bausch Health Americas, Inc.
Opioid-Induced Constipation (OIC)
Assessment of Efficacy and Safety in Patients With Non-cancer-related Pain and Opioid-induced Constipation
The purpose of this study is to evaluate the effect and safety of NKTR-118 treatment of opioid-induced constipation in patients with non-cancer-related pain, including those patients that have inadequate response to laxative…
- Trial name
- NCT01309841
- Testing
- NKTR-118
- Where
- 117 sites in United States, Australia and 2 more
- Volunteers
- 652 people
- Sponsor
- AstraZeneca
Irritable Bowel Syndrome
Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome
The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX1031 versus a placebo control in subjects with non-constipating irritable bowel syndrome.
- Trial name
- NCT00813098
- Testing
- LX1031 High Dose, LX1031 Low Dose
- Where
- 36 sites in United States
- Volunteers
- 155 people
- Sponsor
- Lexicon Pharmaceuticals
Male Subjects With Chronic Constipation
Evaluation of Prucalopride in Male Subjects With Chronic Constipation.
This is a multi-centre, randomised, parallel-group, double-blind, placebo-controlled phase III trial to evaluate the efficacy of prucalopride versus placebo over 12 weeks of treatment in male subjects with chronic constipation.
- Trial name
- NCT01147926
- Testing
- Prucalopride
- Where
- 73 sites in Belgium, Bulgaria and 8 more
- Volunteers
- 374 people
- Sponsor
- Shire
Chronic Idiopathic Constipation
An Efficacy and Safety Study of Plecanatide in Adolescents 12 to <18 Years of Age With Chronic Idiopathic Constipation
This is a study of efficacy and safety of Plecanatide in pediatric subjects aged 12 to < 18 years diagnosed with Chronic Idiopathic Constipation.
- Trial name
- NCT03120520
- Testing
- Plecanatide
- Where
- 36 sites in United States
- Volunteers
- 124 people
- Sponsor
- Bausch Health Americas, Inc.
Constipation
A Safety and Efficacy Evaluation of BLI801 Laxative in Adults Experiencing Non-Idiopathic Constipation
The objective of this study is to evaluate multiple doses of BLI801 Laxative for safety and efficacy versus placebo in adults experiencing non-idiopathic constipation.
- Trial name
- NCT02822508
- Testing
- BLI801 Laxative
- Where
- 73 sites in United States
- Volunteers
- 434 people
- Sponsor
- Braintree Laboratories
Chronic Constipation
Study to Investigate Prucalopride vs. Polyethylene Glycol 3350 on Colon Activity
To evaluate the different effects of prucalopride and PEG 3350 + electrolytes on colon motor activity in subjects that are chronically constipated.
- Trial name
- NCT01707667
- Testing
- prucalopride, PEG 3350
- Where
- 3 sites in United States, Belgium and 1 more
- Volunteers
- 13 people
- Sponsor
- Shire
Irritable Bowel Syndrome With Constipation (IBS-C)
A Study of the Effect of SYN-010 on Subjects With IBS-C
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multi-Dose Study of the Effect of Two Dosage Strengths of SYN-010 Compared with Placebo on Breath Methane Production in Breath Methane-Positive Subjects with…
- Trial name
- NCT02495623
- Testing
- SYN-010 21 mg, SYN-010 42 mg
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Theriva Biologics, Inc.
Constipation
A Preference Study Comparing Kristalose® and Liquid Lactulose
This study will evaluate whether patients have an overall preference for Kristalose® or liquid lactulose based on taste, consistency, and portability.
- Trial name
- NCT00712543
- Testing
- lactulose (Kristalose®), liquid lactulose
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Cumberland Pharmaceuticals
Constipation Predominant Irritable Bowel Syndrome
A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)
This is a multi-center, Phase 2, randomized, double-blind, placebo controlled study of RDX5791 in subjects with IBS-C. Patients who are 18 to 75 years old, meeting the definition of IBS-C as defined by the Rome III Criteria for…
- Trial name
- NCT01340053
- Testing
- RDX5791
- Where
- 16 sites in United States
- Volunteers
- 186 people
- Sponsor
- Ardelyx
Opioid Induced Constipation
Evaluation of the Efficacy and Safety of ADL5945 for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain
Morphine and related opioid analgesics are known to slow gastrointestinal (GI) motility and reduce intestinal secretion through their binding to μ opioid receptors (MORs) within the GI tract.
- Trial name
- NCT01207427
- Testing
- ADL5945 0.1 mg, ADL5945 0.25 mg
- Volunteers
- 131 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Irritable Bowel Syndrome With Constipation
Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
The purpose of this study is to determine the safety, efficacy, and dose response of a range of oral doses of linaclotide administered to patients meeting criteria for IBS-C.
- Trial name
- NCT00460811
- Testing
- Linaclotide Acetate
- Where
- 85 sites in United States, Canada
- Volunteers
- 420 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Joint Diseases, Arthritis
A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease
The purpose of this study is to compare bowel function/constipation that occurs during tapentadol treatment with that occuring during oxycodone treatment, as measured by the frequency of spontaneous bowel movements per week.
- Conditions
- Joint Diseases, Arthritis, Osteoarthritis
- Trial name
- NCT00784277
- Testing
- oxycodone CR, oxycodone IR, Tapentadol ER (CG5503)
- Volunteers
- 597 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Chronic Idiopathic Constipation
Efficacy and Safety Trial of Elobixibat in Patients With Chronic Idiopathic Constipation
12 Week Efficacy and Safety Trial Followed by a 4 Week Withdrawal Period for Patients with Chronic Idiopathic Constipation.
- Trial name
- NCT01833065
- Testing
- Elobixibat 10 mg/day, Elobixibat 5 mg/day
- Where
- 97 sites in United States, Brazil and 10 more
- Volunteers
- 314 people
- Sponsor
- Ferring Pharmaceuticals
Non-Constipation Irritable Bowel Syndrome
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.
- Trial name
- TARGET 1 (NCT00731679)
- Testing
- Rifaximin
- Where
- 96 sites in United States, Canada
- Volunteers
- 623 people
- Sponsor
- Bausch Health Americas, Inc.
Constipation
A Pilot Study to Assess the Efficacy and Safety of Various Vibrating Capsule Modes
The study is a prospective, adaptive, multicenter, randomized, double-blind, Sham-controlled pilot study, to evaluate the efficacy and safety of the Vibrant Capsule in relieving constipation in subjects with functional…
- Trial name
- NCT03329027
- Testing
- Vibrating Capsule
- Where
- 4 sites in United States
- Volunteers
- 67 people
- Sponsor
- Vibrant Ltd.
Chronic Idiopathic Constipation
SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation
This is a Phase 2a, randomized, double-blind, placebo-controlled, 14-day repeat oral, dose ranging study to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) effects of SP-304 in patients with chronic…
- Trial name
- CIC (NCT01053962)
- Testing
- SP-304 0.3 mg, SP-304 1.0 mg, SP-304 3.0 mg
- Where
- 14 sites in United States
- Volunteers
- 84 people
- Sponsor
- Bausch Health Americas, Inc.
Constipation
Safety and Tolerability of Oral Polyethylene Glycol (PEG 3350) Solution in Participants With Constipation (MK-8114-003)
The purpose of this study is to compare the safety and tolerability of oral ingestion of PEG 3350 solution concentrate to oral ingestion of a placebo solution concentrate, in participants with constipation.
- Trial name
- NCT01885104
- Testing
- Polyethylene Glycol (PEG 3350), Bisacodyl laxative tablets (rescue medication)
- Volunteers
- 65 people
- Sponsor
- Bayer